HUMAN GROWTH HORMONE (hGH) APPLICATION REVIEWS are proceeding at FDA for followup products to Genentech's Protropin and Lilly's Humatrope, the agency told Senators Kennedy (D-Mass.) and Hatch (R-Utah) in a Jan. 25 letter (see related story above). Noting that Kennedy and Hatch had asked that pending hGH application reviews be completed by June of this year, FDA reported "the review of those applications is ongoing, and we expect that much of the review work will have been completed by June 1989." The senators had asked FDA to complete its review by June so that any changes in orphan exclusivity provisions could be taken advantage of by the pending hGH products. Lilly's Humatrope has about five years of exclusive marketing rights remaining for its recombinant human growth hormone product. FDA included one proviso in its assurance of a continuing review of the pending hGH applications. The agency noted the exception "of those areas where evolving technology may result in different production methods." Genentech recently defended its pricing and marketing practices for Protropin in a Jan. 17 letter to the National Commission on Orphan Diseases. Noting that the average annual cost of Protropin is $ 12,000, the letter states that the price of Protropin, since its market introduction at "25% less than the price of the two pituitary-derived products that it replaced," has not changed.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
